BioXcel Therapeutics, Inc. (BTAIQ) Gross margin 2022–2025
BioXcel Therapeutics, Inc. (BTAIQ) gross margin by fiscal year — reported gross profit divided by reported revenue.
74.5%FY2025 · since FY2022: 94.7% → 74.5%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 74.5% | +69.0 pp |
| FY2024 | 5.4% | -3.3 pp |
| FY2023 | 8.7% | -86.0 pp |
| FY2022 | 94.7% | — |
Gross margin = reported gross profit ÷ reported revenue for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More BTAIQ financial trends
BTAIQ RevenueBTAIQ Net incomeBTAIQ Net marginBTAIQ Gross profitBTAIQ Operating incomeBTAIQ Operating marginBTAIQ Operating cash flowBTAIQ Free cash flowBTAIQ Capital expendituresBTAIQ Return on equityBTAIQ Stock buybacksBTAIQ Dividends paidBTAIQ Total assetsBTAIQ Total liabilitiesBTAIQ Shareholders’ equityBTAIQ overview →